SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Instytut Innowacji Przemysłowych MAT
Instytut Innowacji Przemysłowych MAT Spółka z Ograniczoną Odpowiedzialnością
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Instytut Innowacji Przemysłowych MAT Spółka z Ograniczoną Odpowiedzialnością
Instytut Innowacji Przemysłowych MAT Spółka z Ograniczoną Odpowiedzialnością (KRS 0000810620, NIP 5213880602) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. Instytut Innowacji Przemysłowych MAT operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since October 25, 2019.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Founded
October 25, 2019
6 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
99 shares total
Shareholders
3
shareholders
Board
1 person
Proxies: 1
Filed years
N/A
Registry entries
10
latest: May 13, 2022
No KPI data - financial statements and valuation are unavailable for this company.
Rate business credibility - Instytut Innowacji Przemysłowych MAT.
No ratings

News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.

News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
Instytut Innowacji Przemysłowych MAT's board has 1 member.
Latest reporting year
2020
Available years
1
Filing entries
0
Competing companies or those operating in the same market segment as Instytut Innowacji Przemysłowych MAT (in Warszawa, industry: Research and development).
WARSZAWA· Research and development
Revenue 2025: 63.8 M PLN
WARSZAWA· Research and development
Revenue 2023: 2.0 M PLN
WARSZAWA· Research and development
Revenue 2023: 298.9 K PLN
WARSZAWA· Research and development
Revenue 2023: 173.9 K PLN
WARSZAWA· Research and development
WARSZAWA· Research and development
10 historical registry entries for Instytut Innowacji Przemysłowych MAT
Representation rule change, Board change, Commercial proxy change, Shareholder change, Articles of association amended
WA.XIII NS-REJ.KRS/23791/21/229
Board change
WA.XIII NS-REJ.KRS/23796/21/234
Shareholder change
WA.XIII NS-REJ.KRS/45729/21/346
Filing documents submitted (3 documents)
Board change
WA.XIII NS-REJ.KRS/1820/22/529